TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38376227

Group type: EXPERIMENTAL
Intervention: VIR-2482
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38376229

Group type: EXPERIMENTAL
Intervention: Posaconazole intravenous (IV) and powder for oral suspension (PFS) formulations at dosing regimens of 3.5, 4.5, and 6 mg/kg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg/day tablet in a virtual adolescent population (body weight >40 kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Posaconazole IV only
Number of subjects: 144
Study: 38376518

Group type: EXPERIMENTAL
Intervention: High-fat food preference measured in fasted state
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sweet food reward measured as implicit wanting
Number of subjects: 7
Study: 38376591

Group type: EXPERIMENTAL
Intervention: Seawater nasal wash (4-daily nasal washes with undiluted isotonic seawater)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Seawater nasal wash
Number of subjects: 355
Study: 38376593

Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction Exercise (CAE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (rehabilitation program without CAE)
Number of subjects: 30
Study: 38376596

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HyA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Presence of plaque
Number of subjects: 56

Group type: COMPARATOR
Intervention: Time
Number of subjects: 56
Study: 38376645

Group type: COMPARATOR
Intervention: Zonisamide 25 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Zonisamide 50 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 38376643

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) + topical timolol-dorzolamide eye drops
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone (Control)
Number of subjects: 46
Study: 38376651

Group type: EXPERIMENTAL
Intervention: 24-week TDF (Arm A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 48-week TDF (Arm B)
Number of subjects: 100
Study: 38376858

Group type: EXPERIMENTAL
Intervention: CBD diagnosis model using clinical, Shape, and Diameter characteristics
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Intrahepatic involvement identification model using clinical, Shape, and Diameter characteristics
Number of subjects: 131
Study: 38376926

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lonsurf (control)
Number of subjects: 40
Study: 38376930

Group type: EXPERIMENTAL
Intervention: Compassion-based meditation intervention delivered via the Healthy Minds Program app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38376992

Group type: EXPERIMENTAL
Intervention: Social support interventions (specific details not provided)
Number of subjects: 0
Study: 38377071

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant transarterial chemoembolization (PA-TACE)
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Proposed HIPC scheme
Number of subjects: 1488
Study: 38377166

Group type: EXPERIMENTAL
Intervention: Facilitated directly observed therapy (DOT)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Facilitated self-administered therapy (SAT)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Informed choice between facilitated DOT and facilitated SAT
Number of subjects: 1655
Study: 38377176

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Carboplatin/Etoposide Q3W for 4-6 cycles in the induction phase, followed by Atezolizumab maintenance Q3W
Number of subjects: 154
Study: 38377234

Group type: EXPERIMENTAL
Intervention: Perivascular inflammation (assessed by pericoronary adipose tissue attenuation) in women
Number of subjects: 409

Group type: COMPARATOR
Intervention: Perivascular inflammation (assessed by pericoronary adipose tissue attenuation) in men
Number of subjects: 409
Study: 38377235

Group type: EXPERIMENTAL
Intervention: Imaging-assessed stress-related neural activity
Number of subjects: 364
Study: 38377256

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38377327

Group type: EXPERIMENTAL
Intervention: Simplified Meal Announcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Precise Carbohydrate Counting
Number of subjects: 0
Study: 38377520

Group type: EXPERIMENTAL
Intervention: Fluoxetine; dosage and duration not available
Number of subjects: 0
Study: 38377518

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study: 38377526

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment without pharmacogenetic testing)
Number of subjects: 0
Study: 38377570

Group type: EXPERIMENTAL
Intervention: Telehealth Intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth Intervention 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (standard care)
Number of subjects: 0
Study: 38377775

Group type: EXPERIMENTAL
Intervention: Matched targeted therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Non-matched treatment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AcSé ESMART trial
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Matched targeted therapy outside a clinical trial
Number of subjects: 93

Group type: COMPARATOR
Intervention: Successful sequencing analysis
Number of subjects: 93
Study: 38377773

Group type: EXPERIMENTAL
Intervention: TLD-1 administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) starting dose of 10 mg/m², maximum administered dose of 45 mg/m², RP2D defined at 40 mg/m².
Number of subjects: 30
Study: 38377869

Group type: EXPERIMENTAL
Intervention: Simvastatin add-on treatment
Number of subjects: 0
Study: 38378313

Group type: EXPERIMENTAL
Intervention: CT angiography-derived fractional flow reserve (FFR)
Number of subjects: 102
Study: 38378482

Group type: EXPERIMENTAL
Intervention: High risk of hospital admission (percentiles 95-100)
Number of subjects: 40618

Group type: COMPARATOR
Intervention: Low risk of hospital admission (percentiles <60)
Number of subjects: 40618

Group type: EXPERIMENTAL
Intervention: High risk of hospital admission (percentiles 85-100)
Number of subjects: 40618
Study: 38378503

Group type: EXPERIMENTAL
Intervention: Family-oriented mental health practice as measured by the Family-Focused Mental Health Practice Questionnaire (FFMHPQ)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Workplace support for family-oriented practice
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Skills and knowledge about the impact of mental illness and parenting
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Institutional support for family-oriented work
Number of subjects: 475
Study: 38378522

Group type: EXPERIMENTAL
Intervention: Collagen patch cover (CPC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no CPC)
Number of subjects: 241
Study: 38378532

Group type: EXPERIMENTAL
Intervention: EM Talk training (4-hour session with role-plays and active learning)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: EM Talk training
Number of subjects: 879
Study: 38378568

Group type: EXPERIMENTAL
Intervention: Kefir administration (60 mL, followed by 120 mL after 12 h, then 240 mL daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Kefir administration
Number of subjects: 54
Study: 38378671

Group type: EXPERIMENTAL
Intervention: Biomimetic neurostimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional approaches
Number of subjects: 0
Study: 38378678

Group type: EXPERIMENTAL
Intervention: Denosumab (RANKL inhibitor)
Number of subjects: 0
Study: 38378685

Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD) - 3 cycles
Number of subjects: 0
Study: 38378735

Group type: EXPERIMENTAL
Intervention: Evidence-based therapies (EBTs) including antithrombotic drugs
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Satisfaction of all domains of secondary prevention
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Overall practice of secondary prevention
Number of subjects: 2003
Study: 38378868

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus durvalumab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus durvalumab (in RAS wild type tumors)
Number of subjects: 29
Study: 38378875

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control phase (no specific intervention mentioned)
Number of subjects: 15
Study: 38378937

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate loading dose
Number of subjects: 50
Study: 38379100

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic gastrectomy (3D-LG)
Number of subjects: 438

Group type: COMPARATOR
Intervention: 2D laparoscopic gastrectomy (2D-LG)
Number of subjects: 438
Study: 38379394

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 35
Study: 38379539

Group type: EXPERIMENTAL
Intervention: AlmegaPL (Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AlmegaPL
Number of subjects: 0
Study: 38379580

Group type: EXPERIMENTAL
Intervention: Compressive draping with adhesive incise drape
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard shoulder arthroscopy drape
Number of subjects: 50
Study: 38379859

Group type: EXPERIMENTAL
Intervention: Preoperative levels of IGFBP2
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Hit-proteins LDHB, VCAM1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All-cause one-year mortality
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Postoperative myocardial infarction
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Stroke until hospital discharge
Number of subjects: 192
Study: 38379866

Group type: EXPERIMENTAL
Intervention: Individualized resistance exercise program (at least 3 times per week over a 24-week period)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Individualized resistance exercise program
Number of subjects: 52
Study: 38380071

Group type: EXPERIMENTAL
Intervention: OCTANE (multi-gene panel testing)
Number of subjects: 782
Study: 38380342

Group type: EXPERIMENTAL
Intervention: Cancer symptom management intervention
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Adaptation tracking
Number of subjects: 187
Study: 38380420

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10 mg (TEL/ALD/RSV)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/Atorvastatin 10 mg (ALD/ATV)
Number of subjects: 252
Study: 38380438

Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with no versus only mild nausea, vomiting, sedation, and dizziness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with mild versus moderate nausea, vomiting, sedation, and dizziness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with moderate versus severe nausea, vomiting, sedation, and dizziness
Number of subjects: 0
Study: 38380649

Group type: EXPERIMENTAL
Intervention: Interesterified palmitic acid-rich spread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-interesterified spread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spreadable butter
Number of subjects: 0
Study: 38380699

Group type: EXPERIMENTAL
Intervention: L-serine treatment for 52 weeks
Number of subjects: 24
Study: 38380779

Group type: EXPERIMENTAL
Intervention: Thin buccal bone group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thick buccal bone group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 38380807

Group type: EXPERIMENTAL
Intervention: Acyclic retinoid (ACR) treatment for 4 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pre- and post-surgical patients with HCC
Number of subjects: 116

Group type: COMPARATOR
Intervention: Patients with HCC
Number of subjects: 116
Study: 38380940

Group type: EXPERIMENTAL
Intervention: Standard initiation of Renal Replacement Therapy (RRT)
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: Accelerated initiation of Renal Replacement Therapy (RRT)
Number of subjects: 2693

Group type: COMPARATOR
Intervention: Control group (ANZ)
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: Regional practice variation
Number of subjects: 2693
Study: 38380992

Group type: EXPERIMENTAL
Intervention: Real-time machine learning alerts sent to primary team or rapid response team (RRT)
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Standard RRT activation criteria (control group)
Number of subjects: 2740
Study: 38381061

Group type: EXPERIMENTAL
Intervention: KeraKlear (KK) foldable intrastromal keratoprosthesis
Number of subjects: 38
Study: 38381068

Group type: EXPERIMENTAL
Intervention: Recreational drug users (41 patients, 12.6% positive multidrug test)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Recreational drug users
Number of subjects: 325

Group type: COMPARATOR
Intervention: Non-recreational drug users (control group)
Number of subjects: 325
Study: 38381283

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH)-targeted therapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 212
Study: 38381407

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg per day)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 38381417

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham acupuncture (minimal needling, 1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 93
Study: 38381476

Group type: EXPERIMENTAL
Intervention: Internet-Based Cognitive Behavioral Therapy (ICBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 33
Study: 38381493

Group type: EXPERIMENTAL
Intervention: Group, blended eMBCT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Individual, unguided eMBCT
Number of subjects: 24
Study: 38381495

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Physician feedback
Number of subjects: 4

Group type: COMPARATOR
Intervention: Patient education and physician feedback
Number of subjects: 4
Study: 38381664

Group type: EXPERIMENTAL
Intervention: Seladelpar (10 mg daily)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 38381674

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease group
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Cognitive assessments in Alzheimer's disease group
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Brain imaging in Alzheimer's disease group
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Matched cognitively normal group
Number of subjects: 1296
Study: 38381675

Group type: EXPERIMENTAL
Intervention: Rusfertide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rusfertide and Placebo
Number of subjects: 70
Study: 38381752

Group type: EXPERIMENTAL
Intervention: Youth-friendly community-based package of HIV services integrated with sexual and reproductive health services
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Community delivery of antiretroviral therapy (ART)
Number of subjects: 1539
Study: 38381905

Group type: EXPERIMENTAL
Intervention: Micronized/ultramicronized palmitoylethanolamide (m/umPEA) 600 mg twice daily for 3 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (did not accept m/umPEA therapy)
Number of subjects: 98
Study: 38381930

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug in combination with paracetamol for 3 weeks
Number of subjects: 101
Study: 38381948

Group type: EXPERIMENTAL
Intervention: Longer acting injectable PrEP (LA PrEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study: 38381994

Group type: EXPERIMENTAL
Intervention: Elacestrant
Number of subjects: 478

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 478
Study: 38382001

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 0
Study: 38382095

Group type: EXPERIMENTAL
Intervention: Machine learning classifier models using LAS-breathprints
Number of subjects: 135

Group type: COMPARATOR
Intervention: VOC-trained classifier model
Number of subjects: 135
Study: 38382153

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 720
Study: 38382311

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 372
Study: 38382419

Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention
Number of subjects: 509
Study: 38382698

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) profiles for copy number variations (CNVs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Other CNVs (not whole chromosome)
Number of subjects: 120
Study: 38382700

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 545
Study: 38382813

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg up to every 16 weeks (Q16W)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 1326
Study: 38382823

Group type: EXPERIMENTAL
Intervention: COVID-19 risk communication intervention
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study: 38382875

Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Durvalumab
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study: 38382912

Group type: EXPERIMENTAL
Intervention: Procedure-specific simulation skills training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 83
Study: 38382951

Group type: EXPERIMENTAL
Intervention: Avoiding postoperative chest drains
Number of subjects: 2

Group type: COMPARATOR
Intervention: Routine postoperative chest drains
Number of subjects: 2
Study: 38382960

Group type: COMPARATOR
Intervention: 18F-FDG PET imaging
Number of subjects: 18

Group type: COMPARATOR
Intervention: 68Ga-DOTANOC PET imaging
Number of subjects: 18

Group type: COMPARATOR
Intervention: Correlation of uptake of 18F-FDG or 68Ga-DOTANOC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 18
Study: 38383005

Group type: EXPERIMENTAL
Intervention: Preemptive IV acetaminophen 15 mg/kg after anesthetic induction/before surgical incision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Preventive IV acetaminophen 15 mg/kg at the end of surgery/before skin closure
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 38383268

Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT), 8-week intervention (5 sessions per week)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT)
Number of subjects: 33
Study: 38383304

Group type: EXPERIMENTAL
Intervention: Female operators
Number of subjects: 8586

Group type: COMPARATOR
Intervention: Male operators
Number of subjects: 8586

Group type: EXPERIMENTAL
Intervention: Male operator gender
Number of subjects: 8586
Study: 38383310

Group type: EXPERIMENTAL
Intervention: Stool-based qPCR for TB diagnosis
Number of subjects: 1945
Study: 38383323

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory strategies
Number of subjects: 0
Study: 38383345

Group type: EXPERIMENTAL
Intervention: Opioid maintenance treatment (OMT)
Number of subjects: 176
Study: 38383367

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) - 3 months of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP) - 3 months of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 0
Study: 38383418

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging-guided personalized rTMS (fMRI-rTMS), high-frequency rTMS (10 Hz, 120% MT), 15 consecutive days, 30 minutes per session
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham stimulation (control group), coil flipped to 90 degrees, 15 consecutive days, 30 minutes per session
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging-guided personalized rTMS (fMRI-rTMS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 80
Study: 38383426

Group type: EXPERIMENTAL
Intervention: Digital psychological self-care (DPSC) with mid-treatment interview guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital psychological self-care (DPSC) with weekly written messages guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digital psychological self-care (DPSC) without guidance
Number of subjects: 0
Study: 38383458

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Best-performing predictive models
Number of subjects: 417

Group type: COMPARATOR
Intervention: Chemotherapy (control arm)
Number of subjects: 417
Study: 38383461

Group type: EXPERIMENTAL
Intervention: Laparoscopic left-sided hepatectomy (LLH)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Open left-sided hepatectomy (OLH)
Number of subjects: 172